A detailed history of Core First Bank & Trust transactions in Biogen Inc. stock. As of the latest transaction made, Core First Bank & Trust holds 304 shares of BIIB stock, worth $41,517. This represents 0.03% of its overall portfolio holdings.

Number of Shares
304
Previous 304 -0.0%
Holding current value
$41,517
Previous $58,000 20.69%
% of portfolio
0.03%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Feb 11, 2025

BUY
$189.07 - $236.8 $57,477 - $71,987
304 New
304 $58,000
Q2 2022

Aug 16, 2022

SELL
$187.54 - $223.02 $37,508 - $44,604
-200 Reduced 39.68%
304 $62,000
Q1 2022

May 16, 2022

BUY
$193.77 - $244.14 $58,906 - $74,218
304 Added 152.0%
504 $106,000
Q4 2021

Feb 10, 2022

SELL
$223.92 - $287.77 $55,980 - $71,942
-250 Reduced 55.56%
200 $48,000
Q4 2020

Feb 16, 2021

BUY
$236.26 - $355.63 $106,317 - $160,033
450 New
450 $110,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $19.7B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Core First Bank & Trust Portfolio

Follow Core First Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core First Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Core First Bank & Trust with notifications on news.